HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Vindesine (Vindesin)

Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).

Also Known As:

Vindesin; Vindesine Sulfate; Compound 112531; Desacetylvinblastine Amide; EG Labo Brand of Vindesine Sulfate; Eldisine; Enison; Lilly Brand of Vindesine Sulfate; NSC-245467; NSC 245467; NSC245467; Sulfate, Vindesine; Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-

Networked: 756 relevant articles (55 outcomes, 265 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- Alkaloids: 1065
  - Indole Alkaloids: 36
    - Secologanin Tryptamine Alkaloids: 55
      - Vinca Alkaloids: 337
        Vindesine: 756
        MiPE protocol: 8
        PCV regimen: 6
        VDA-P protocol: 4
        LNH 87 protocol: 3
        LNH-80 regimen: 3
        LSG15 regimen: 3
        HELP protocol: 2
        CAD protocol 2: 1
        LNH 84 protocol: 1
        LNH87-2 protocol: 1
        MICE regimen: 1
        MV protocol 2: 1
        N-(4-azidobenzoyl)-N'-beta-aminoethylvindesine: 1
        OPP-EBV-CAD regimen: 1
        OS 87 protocol: 1
        VEP protocol: 1
        VMMc protocol: 1
        APEL protocol
        BELD protocol
        BEMP protocol 2
        CAD protocol 1
        CAPE protocol
        CEVD protocol
        Cis-VACD protocol
        CVB protocol
        DAC protocol
        DECAV protocol
        DVP protocol
        EBAP protocol
        ELETOP protocol
        EPVP protocol
        EV protocol
        EVI protocol
        HR-2 protocol
        IVEP protocol
        MB-triple V protocol
        MCNU-VMP protocol
        MOPPEBVCAD protocol
        MTV protocol
        N-(4-azido-3-iodosalicyl)-N'-beta-aminoethylvindesine
        PECC protocol
        PEEC protocol
        PEEC-M protocol
        VAE protocol
        VCH protocol
        VCPC protocol
        VEMP protocol 3
        VINAP protocol
        VinMCP protocol
        VIP protocol 3
        VPIV protocol
        VQEP protocol
- 2-Ring Heterocyclic Compounds
  - Indoles: 95
    - Indole Alkaloids: 36
      - Secologanin Tryptamine Alkaloids: 55
        Vinca Alkaloids: 337
        Vindesine: 756
        MiPE protocol: 8
        PCV regimen: 6
        VDA-P protocol: 4
        LNH 87 protocol: 3
        LNH-80 regimen: 3
        LSG15 regimen: 3
        HELP protocol: 2
        CAD protocol 2: 1
        LNH 84 protocol: 1
        LNH87-2 protocol: 1
        MICE regimen: 1
        MV protocol 2: 1
        N-(4-azidobenzoyl)-N'-beta-aminoethylvindesine: 1
        OPP-EBV-CAD regimen: 1
        OS 87 protocol: 1
        VEP protocol: 1
        VMMc protocol: 1
        APEL protocol
        BELD protocol
        BEMP protocol 2
        CAD protocol 1
        CAPE protocol
        CEVD protocol
        Cis-VACD protocol
        CVB protocol
        DAC protocol
        DECAV protocol
        DVP protocol
        EBAP protocol
        ELETOP protocol
        EPVP protocol
        EV protocol
        EVI protocol
        HR-2 protocol
        IVEP protocol
        MB-triple V protocol
        MCNU-VMP protocol
        MOPPEBVCAD protocol
        MTV protocol
        N-(4-azido-3-iodosalicyl)-N'-beta-aminoethylvindesine
        PECC protocol
        PEEC protocol
        PEEC-M protocol
        VAE protocol
        VCH protocol
        VCPC protocol
        VEMP protocol 3
        VINAP protocol
        VinMCP protocol
        VIP protocol 3
        VPIV protocol
        VQEP protocol

Experts

1.	Schadendorf, Dirk: 5 articles (12/2011 - 03/2002)
2.	Federico, Massimo: 4 articles (11/2011 - 12/2005)
3.	Kiura, Katsuyuki: 4 articles (06/2011 - 03/2002)
4.	Segawa, Yoshihiko: 4 articles (06/2011 - 06/2002)
5.	Ueoka, Hiroshi: 4 articles (06/2011 - 03/2002)
6.	Tabata, Masahiro: 4 articles (06/2011 - 03/2002)
7.	Tanimoto, Mitsune: 4 articles (06/2011 - 03/2002)
8.	Eiter, Helmut: 4 articles (05/2009 - 10/2004)
9.	Rhomberg, Walter: 4 articles (05/2009 - 10/2004)
10.	Ichinose, Yukito: 4 articles (02/2008 - 02/2003)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/01/1990 - "Since STS has been proven clinically effective in reducing such side effects, we initiated a study of STS in patients with advanced non-small-cell lung carcinoma who were given a combination of CDDP and vindesine (VDS) systemically. " 01/01/1989 - "In this study, 61 patients with non-small-cell lung carcinoma were randomized to receive either CDDP and vindesine (both given i.v.) with i.v. STS [30 patients, STS(+) group] or CDDP and vindesine without STS [31 patients, STS(-) group]. " 08/01/1987 - "[A phase II study of vindesine for pretreated non-small cell lung cancer]." 09/01/1985 - "A phase II study of vindesine (VDS) was carried out in 21 patients with non-small cell lung cancer (NSCLC). " 09/01/1985 - "Phase II study of vindesine in patients with non-small cell lung cancer."
2.	Neoplasms (Cancer) 01/01/1993 - "The efficacy of the association of cisplatinum-mitomycine and vindesine on inoperable non-small cell bronchial cancer has been assessed in a prospective study. " 06/01/1986 - "Phase II study of vindesine in the treatment of pediatric patients with solid tumors: a report from the Childrens Cancer Study Group." 09/01/1983 - "[A cooperative phase II study of vindesine sulfate in patients with solid tumors]." 01/01/1983 - "Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer." 09/01/1980 - "Vindesine trials at Memorial Sloan-Kettering Cancer Center."
3.	Breast Neoplasms (Breast Cancer) 09/01/1981 - "Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion." 10/01/1984 - "The results--together with the results of other single-agent studies of vindesine summarized in the paper--indicate that the drug is an active agent in advanced breast cancer. " 09/01/1982 - "Vindesine, a new vinca alkaloid, was administered to 20 patients with advanced refractory breast cancer in a phase II trial. " 09/01/1982 - "Phase II study of vindesine in patients with advanced breast cancer." 07/01/1981 - "Phase II study of vindesine in patients with metastatic breast cancer."
4.	Neoplasm Metastasis (Metastasis) 04/01/2000 - "Ten months later, he developed liver metastases and was treated with vindesine (12 months) and interferon-alpha-2a (30 months) resulting in complete remission which has been maintained for over 10 years. " 06/01/2001 - "Since liver metastasis recurred after initial treatment, chemotherapy consisting of NDP infusion combined with vindesine sulfate (VDS) infusion was performed. " 01/01/2000 - "The diagnosis was established with proctoscopy and biopsy, and a palliative abdominoperineal resection in the presence of lymph node metastases was performed followed by chemotherapy with vindesine. " 07/01/1997 - "For patients with refractory breast cancer, especially with bone metastasis, chemoendocrine therapy containing vindesine might have therapeutic efficacy with low toxicity and favorable quality of life." 01/01/1988 - "[Remarkable effect of vindesine sulfate (VDS) in the treatment of metachronous lung metastasis of esophageal cancer--a case report]."
5.	Melanoma (Melanoma, Malignant) 10/01/2008 - "Adjuvant treatment with vindesine did not significantly prolong disease free or overall survival in high-risk melanoma patients. " 04/01/2009 - "Adjuvant treatment with vindesine for metastatic melanoma: in response to the study of Eigentler et al. (2008)." 09/01/1984 - "Multicenter phase II trial with 5-day continuous infusion of vindesine in metastatic malignant melanoma." 04/01/1984 - "A phase II study using vindesine (3 mg/m2 by slow intravenous push at seven to 14 day intervals) was carried out in 42 patients with metastatic melanoma. " 04/01/1984 - "Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study."

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Cyclophosphamide (Cytoxan)
3.	Vincristine (Oncovin)
4.	Doxorubicin (Adriamycin)
5.	Prednisone (Sone)
6.	Mitomycin (Mitomycin-C)
7.	Etoposide (VP 16)
8.	Prednisolone (Predate)
9.	Ifosfamide
10.	Bleomycin (Blenoxane)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Radiotherapy
4.	Adjuvant Chemotherapy
5.	Heterologous Transplantation (Xenotransplantation)